🇺🇸 FDA
Pipeline program

Selinexor

20-12023093

Phase 2 small_molecule terminated

Quick answer

Selinexor for Myeloma Multiple is a Phase 2 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Karyopharm Therapeutics
Indication
Myeloma Multiple
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials